Skip to main content
. 2015 Aug;70(8):550–555. doi: 10.6061/clinics/2015(08)04

Figure 2.

Figure 2

Kaplan-Meier survival analysis. Five-year PFS of chronic myeloid leukemia patients treated with a 3rd tyrosine kinase inhibitor according to disease phase.